Novocure
NVCR----
Q2 FY2026 EarningsQ2 FY26 net revenues reached $183.6M, up 16% YoY, driven by an 18% increase in global active patients to 5,128. Gross margin expanded to 77.6% (up 3.7pct YoY), supported by a $4.9M tariff refund and improved manufacturing efficiencies. Operating loss significantly narrowed to $10.6M from $39.5M in the prior year, while Adjusted EBITDA turned positive at $10.8M. Net loss per share was $0.13 compared to $0.36 in Q2 FY25.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Novocure(NVCR) predict that the Revenue is 183.58 M (+15.6%), Beat estimate;the EBIT is -10.56 M (+73.27%), Beat estimate;the EPS is -0.13 (+63.89%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.18B15.60%
0.17B8.58%
+0.01B7.02%
EBITExceed expectations
-0.01B73.27%
-0.03B16.12%
+0.02B57.15%
EPSExceed expectations
-0.1363.89%
-0.33177.87%
+0.201756.02%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf